The Food and Drug Administration announced that its safety review of the nation's primary abortion pill, mifepristone, will extend into next year. This timeline was met with swift condemnation from abortion opponents who had hoped for earlier restrictions on the drug's use.
The FDA provided this update on the controversial reevaluation in a legal filing late Wednesday. Mifepristone was first approved by the agency in 2000 and has since had several restrictions eased, including a previous requirement for in-person dispensing. The agency has consistently reaffirmed the pill's safety and effectiveness over the years.
However, anti-abortion groups and their allies have intensified efforts to revisit the drug's status since former President Donald Trump returned to the White House. The FDA indicated in its filing that it expects to complete a safety study of the pill by mid-December of this year. A report detailing the findings is anticipated no later than March 2027, after which the agency will determine whether to implement new restrictions or other changes to the drug's availability.
Gavin Oxley of Americans United for Life criticized the prolonged review, stating that the administration is not prioritizing women's health and appears to be "clearly uninterested in mitigating the ongoing harms caused by the abortion pill."
The two-drug regimen of mifepristone, typically used with misoprostol, is the most common method for abortions in the U.S. The FDA's update was mandated by a federal judge presiding over a lawsuit filed by Louisiana. The state alleges that mail-delivery of mifepristone conflicts with its abortion ban. This is one of several state-level lawsuits challenging mifepristone's accessibility.
Earlier this month, a three-judge panel for the 5th U.S. Circuit Court of Appeals questioned the legal standing of Louisiana's case. Regardless of the outcome in the 5th Circuit, any ruling would not immediately alter the current landscape, as the Supreme Court has placed a hold on changes to the drug's status pending further review.
The FDA stated that it is employing a "statistical data mining method" to identify potential unknown safety concerns associated with mifepristone. This data is drawn from an electronic database that compiles reports of medical injuries and drug side effects from major health networks and insurers. In addition to the safety study, the agency is considering various petitions that propose alterations to how mifepristone is prescribed and distributed. Anti-abortion advocates have particularly focused on a 2021 decision, made permanent under President Joe Biden in 2023, that allowed the drug to be prescribed via telehealth and mailed, which has impacted numerous state abortion bans.